mogamulizumab: clinical use

Prescribing considerations

• Initiate and supervise treatment through clinicians experienced in cancer treatment, with resuscitation facilities available.
• Assess active infection, previous infusion or severe skin reactions, cardiac risk and planned or previous stem-cell transplantation.
• Test for hepatitis B before treatment; seek hepatitis expertise for current or previous infection because reactivation may occur.
• Consider tumour-lysis risk in rapidly proliferating or high-burden disease.
• Record the product name and batch number for biological traceability.

Contraindications and cautions

• Hypersensitivity to mogamulizumab or any listed excipient.

Monitoring

• Observe during and after infusions for acute reactions, particularly early in treatment.
• Monitor for new or worsening rash and assess promptly for severe cutaneous reactions.
• Monitor for infection and viral reactivation throughout treatment.
• For patients at tumour-lysis risk, monitor hydration, renal function and electrolytes closely.
• After subsequent allogeneic transplantation, monitor closely for graft-versus-host disease and other transplant complications.

Clinical pharmacology

Mogamulizumab is a defucosylated humanised IgG1 kappa antibody targeting CCR4. It depletes CCR4-expressing cells and is expected to undergo IgG-like catabolism into peptides and amino acids; its mean elimination half-life is approximately 17 days.

Formulation and product differences

• The selected product is a clear to slightly opalescent, colourless concentrate requiring dilution in sodium chloride solution before intravenous infusion.
• It is preservative-free and supplied as a single-use vial; unused contents are discarded.
• It must not be mixed or co-infused in the same intravenous line with other medicines.

Solution for infusion

Route: Intravenous

Strengths: 4 mg/mL